DR. MICHAEL ANTHONY CILIBERTO MD
Prescription History 1043418809
Psychiatry & Neurology - Epilepsy in Iowa City, IA

NPI Status: Active since July 03, 2007

Contact Information

200 HAWKINS DR
IOWA CITY, IA
ZIP 52242
Phone: (319) 356-7726
Fax: (319) 384-8818

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MICHAEL ANTHONY CILIBERTO MD, an active Epilepsy specialist practicing in Iowa City, IA. Our medical registry currently tracks 17 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 370 documented patient claims. Among these therapy options, the most frequently utilized medication is Oxcarbazepine, which accounts for 40 claims alone.


Banzel

Generic Formulation: RufinamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.2
Days Supply 428
IA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills39.3
Peer Average Days Supply640
Conservative Utilization

This provider writes prescriptions for this formulation 25.6% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,633.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,297.70

State Avg Cost Per Claim

$2,616.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.

Clobazam

Generic Formulation: ClobazamSpecialty: Neurology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.4
Days Supply 967
IA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply879
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,082.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$471.33

State Avg Cost Per Claim

$239.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Clonazepam

Generic Formulation: ClonazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 341
IA State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills58.0
Peer Average Days Supply1,615
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.9% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $615.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.28

State Avg Cost Per Claim

$8.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
IA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply945
Conservative Utilization

This provider writes prescriptions for this formulation 48.4% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $469.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.32

State Avg Cost Per Claim

$64.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Divalproex Sodium Er

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
IA State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills48.8
Peer Average Days Supply1,349
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,090.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$171.69

State Avg Cost Per Claim

$105.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Epidiolex

Generic Formulation: Cannabidiol (Cbd)Specialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply1,084
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.7% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $82,661.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,888.42

State Avg Cost Per Claim

$3,437.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound isolated from Cannabis sativa extract.

Therapeutic Applications

This medication is used to treat seizures due to certain medical conditions (such as Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex - TSC). It is not known how this medication works for these seizures. Cannabidiol belongs to a class of drugs known as cannabinoids.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 34.0
Days Supply 702
IA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills40.3
Peer Average Days Supply1,053
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,850.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$86.38

State Avg Cost Per Claim

$289.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.2
Days Supply 841
IA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills77.3
Peer Average Days Supply2,231
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $442.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.81

State Avg Cost Per Claim

$14.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 27
30-Day Fills 52.1
Days Supply 1,483
IA State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills59.6
Peer Average Days Supply1,678
Conservative Utilization

This provider writes prescriptions for this formulation 35.7% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,187.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$81.03

State Avg Cost Per Claim

$39.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Levocarnitine

Generic Formulation: LevocarnitineSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills18.1
Peer Average Days Supply501
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $951.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$79.25

State Avg Cost Per Claim

$66.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.

Therapeutic Applications

This medication is used to prevent and treat low blood levels of carnitine. Carnitine is a substance made in the body from meat and dairy products. It helps the body use certain chemicals (long-chain fatty acids) for energy and to keep you in good health. Low blood levels of carnitine may occur in people whose bodies cannot properly use carnitine from their diets, people on dialysis due to serious kidney disease, and people being treated with certain drugs (such as valproic acid, zidovudine). Carnitine levels that are too low can cause liver, heart, and muscle problems. The injectable form of this drug is recommended if you have serious kidney disease (such as ESRD/dialysis) because high doses of the form taken by mouth may increase the risk of serious side effects. Consult your doctor or pharmacist for details.

Nayzilam

Generic Formulation: MidazolamSpecialty: Neurology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 276
IA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply426
Conservative Utilization

This provider writes prescriptions for this formulation 36.7% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,194.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,115.51

State Avg Cost Per Claim

$883.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.

Therapeutic Applications

This medication is used by people with epilepsy to treat a certain type of serious seizure that doesn't stop (seizure clusters). Midazolam belongs to a class of drugs known as benzodiazepines. It may work by increasing the effect of a certain substance in your body (GABA), which helps calm the brain and nerves.

Oxcarbazepine

Generic Formulation: OxcarbazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 40
30-Day Fills 48.0
Days Supply 684
IA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply1,025
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.9% more claims than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,094.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$127.37

State Avg Cost Per Claim

$60.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Rufinamide

Generic Formulation: RufinamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.4
Days Supply 381
IA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills47.1
Peer Average Days Supply1,076
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.6% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,683.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$905.95

State Avg Cost Per Claim

$1,514.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.

Topiramate

Generic Formulation: TopiramateSpecialty: Neurology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.4
Days Supply 730
IA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills52.4
Peer Average Days Supply1,525
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $726.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.25

State Avg Cost Per Claim

$17.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.

Therapeutic Applications

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache, treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room). Topiramate is known as an anticonvulsant or antiepileptic drug.

Valproic Acid

Generic Formulation: Valproic Acid (As Sodium Salt)Specialty: Neurology
Provider Metrics Summary
Total Claims 17
30-Day Fills 20.1
Days Supply 573
IA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills15.9
Peer Average Days Supply430
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $335.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.76

State Avg Cost Per Claim

$55.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Vimpat

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 720
IA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills41.2
Peer Average Days Supply1,014
Conservative Utilization

This provider writes prescriptions for this formulation 35.1% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,580.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,024.19

State Avg Cost Per Claim

$927.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Xcopri

Generic Formulation: CenobamateSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.1
Days Supply 334
IA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.5
Peer Average Days Supply834
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,332.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,333.24

State Avg Cost Per Claim

$1,199.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of seizure disorder (partial onset). It is not known exactly how it works, but it may affect the action of some nerves that cause seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MICHAEL ANTHONY CILIBERTO MD provides transparency into local medical care patterns within Iowa City, IA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Epilepsy ** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.